TUCSON, Ariz., Nov. 12, 2018 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview the Canaccord Medical Technology & Diagnostics conference being held November 15, 2018 at the Westin St. Francis Hotel in New York City, and Shaun McMeans, Chief Financial Officer, will meet with investors on a 1×1 basis at the Craig Hallum Alpha Select Conference being held November 15, 2018 at the Sheraton New York Times Square Hotel. Details of both meetings are as follows:
| Canaccord Medical Technology & Diagnostics Conference | ||
| Date: Time: Location: |
Thursday, November 15 11:00 am Eastern Time Westin St. Francis Hotel |
|
| Craig Hallum Alpha Select Conference | ||
| Date: Time: Location: |
Thursday, November 15 1×1 meetings Sheraton New York Times Square Hotel |
|
About HTG:
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 535-7742
Email: [email protected]
TJ Johnson
Chief Executive Officer
HTG Molecular Diagnostics
Email: [email protected]
